Pharma News

Sangamo BioSciences, Inc. announced the presentation of new preclinical data in disease models from its In Vivo Protein Replacement Platform™ (IVPRP) programs for MPS I (Hurler syndrome) and MPS II (Hunter syndrome). The data demonstrate that the Company's IVPRP approach enabled stable production of therapeutic levels of replacement enzyme from the liver into the circulation and secondary tissues, including the brain, resulting in significant reduction in biomarkers of the disease and, importantly, statistically significant improvements in cognitive function in treated animals.

Sanofi and its specialty care global business unit Sanofi Genzyme presented data from NEO1, its Phase 1/2 clinical study evaluating the investigational novel enzyme replacement therapy neoGAA in 24 patients with late-onset Pompe disease.

Decreased opioid use prior to joint replacement surgery has been linked with improved patient satisfaction and outcomes, fewer complications and a reduced need for post-surgical opioids, according to two new studies.

A Zika virus-laden mosquito bite may infect and kill a type of brain cell, vital for the development of the brain, says a new study conducted in lab grown human cells.

Regular usage of aspirin is likely to reduce the overall risk of cancer, a reduction that primarily reflects a lower risk of colorectal cancer and other tumours of the gastrointestinal tracts, finds a new study.

One day National Conference sponsored partly by Gujarat Council of Science & Technology (GUJCOST) was organised by Bhagwan Mahavir College of Pharmacy, Surat, on the theme of “Emerging Trends in Pharmaceutical Sciences and Regulatory Affairs” at the college campus on 6^th February, 2016. About 182 students from various pharmacy colleges, delegates from industry and faculty from various pharmacy colleges are participated in the conference.

In an advance towards an effective treatment against the deadly Ebola virus disease, researchers have found that an antiviral compound that blocks the virus's ability to replicate can fully protect monkeys when treated three days after infection.

AstraZeneca announced that it has entered into an agreement with ProStrakan Group, a subsidiary of Kyowa Hakko Kirin Co. Ltd., for the rights to Moventig (naloxegol) in the European Union (EU), Iceland, Norway, Switzerland and Liechtenstein. Moventig is the first once-daily, oral peripherally-acting mu-opioid receptor antagonist (PAMORA) approved in Europe for the treatment of opioid-induced constipation (OIC) in adult patients who have had an inadequate response to laxative(s).

BioMarin Pharmaceutical Inc. Announced that BMN 270, an investigational gene therapy for the treatment of patients with hemophilia A, has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA). BioMarin is currently conducting a Phase 1/2 study to evaluate the safety and efficacy of BMN 270 gene therapy in up to 12 patients with severe hemophilia A and will provide a program update in April.  BMN 270 is an AAV 5 factor VIII vector, designed to restore factor VIII plasma concentrations, essential for blood clotting in patients with hemophilia A.